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Disruption of the autoinhibited state primes the E3
ligase parkin for activation and catalysis
Atul Kumar1,†, Jacob D Aguirre2,†, Tara EC Condos2,†, R Julio Martinez-Torres1,†, Viduth K Chaugule1,
Rachel Toth1, Ramasubramanian Sundaramoorthy3, Pascal Mercier2, Axel Knebel1, Donald E Spratt2,
Kathryn R Barber2, Gary S Shaw2,* & Helen Walden1,**
Abstract
The PARK2 gene is mutated in 50% of autosomal recessive juvenile
parkinsonism (ARJP) cases. It encodes parkin, an E3 ubiquitin ligase
of the RBR family. Parkin exists in an autoinhibited state that is
activated by phosphorylation of its N-terminal ubiquitin-like (Ubl)
domain and binding of phosphoubiquitin. We describe the 1.8 Å
crystal structure of human parkin in its fully inhibited state and
identify the key interfaces to maintain parkin inhibition. We identify
the phosphoubiquitin-binding interface, provide a model for the
phosphoubiquitin–parkin complex and show how phosphorylation of
the Ubl domain primes parkin for optimal phosphoubiquitin binding.
Furthermore, we demonstrate that the addition of phosphoubiquitin
leads to displacement of the Ubl domain through loss of structure,
unveiling a ubiquitin-binding site used by the E2~Ub conjugate, thus
leading to active parkin. We find the role of the Ubl domain is to
prevent parkin activity in the absence of the phosphorylation
signals, and propose a model for parkin inhibition, optimization for
phosphoubiquitin recruitment, release of inhibition by the Ubl
domain and engagement with an E2~Ub conjugate. Taken together,
this model provides a mechanistic framework for activating parkin.
Keywords enzyme mechanism; Parkinson’s disease; phosphorylation;
ubiquitination; ubiquitin ligase
Subject Categories Molecular Biology of Disease; Post-translational
Modifications, Proteolysis & Proteomics; Structural Biology
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder with
severe motor and non-motor symptoms (Goedert et al, 2013). There
are several genes associated with PD, with autosomal recessive
juvenile parkinsonism (ARJP) being the most prevalent familial
form of the disease. Mutations in PARK2 and PARK6 genes lead to
ARJP, with PARK2 mutations causing > 50% of cases (Bonifati et al,
2002). PARK2 encodes parkin, an E3 ubiquitin ligase, while PARK6
encodes PTEN-induced kinase 1 (PINK1), which phosphorylates
Ser65 of parkin and ubiquitin.
Parkin is an RBR-type ubiquitin ligase which is characterized by
RING1, inBetweenRING (IBR) and RING2 domains. Recent studies
have suggested these names do not accurately reflect the structures
or functionality of the domains. As a result, an alternative nomencla-
ture that uses RING1, Benign Rcat (BRcat=IBR) and Required for
catalysis (Rcat=RING2) domains has been proposed for all RBR E3
ligases (Spratt et al, 2014) that maintain the familiar RBR scheme.
RBR ligases contain domains additional to the signature RBR module
that are specific to each member. Parkin has an N-terminal ubiqui-
tin-like domain (Ubl) that shares 65% sequence similarity with ubiq-
uitin, and a zinc-chelating RING0 domain immediately N-terminal to
the RBR domains (Hristova et al, 2009). The RING1 domain recruits
E2 enzymes, which carry charged ubiquitin and pass it to a catalytic
cysteine in the parkin RING2 domain (Wenzel et al, 2011). Parkin
can function with multiple E2s and catalyses the formation of several
modifications including K63-linked and K48-linked chains, and
monoubiquitination. Pathogenic mutations occur throughout Parkin,
and mutations in different domains have different effects on activity,
solubility and stability (Wang et al, 2005; Hampe et al, 2006; Safadi
& Shaw, 2007; Safadi et al, 2011; Spratt et al, 2013). Wild-type
parkin exists in an autoinhibited state (Chaugule et al, 2011); subse-
quently, autoinhibition has been demonstrated to be common to
RBR ligases (Smit et al, 2012; Stieglitz et al, 2012; Duda et al, 2013).
The N-terminal Ubl domain inhibits parkin activity, and patho-
genic mutations in this domain render parkin active (Chaugule et al,
2011). High-resolution crystal structures of parkin’s RING0-RBR
domains, which lack the Ubl domain, revealed multiple domain–
domain interactions that regulate parkin activity (Chaugule et al,
2011; Riley et al, 2013; Trempe et al, 2013; Wauer & Komander,
2013). However, the importance of the Ubl domain is highlighted by
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recent findings that PINK1, the kinase encoded by PARK6, phospho-
rylates parkin at serine 65, and this phosphorylation enhances parkin
activity (Kondapalli et al, 2012; Shiba-Fukushima et al, 2012, 2014).
PINK1 also modifies ubiquitin at the equivalent serine 65 (Kane et al,
2014; Kazlauskaite et al, 2014b; Koyano et al, 2014), and this signal
is necessary for parkin activation. Together, these phosphorylation
signals enable parkin to ubiquitinate multiple substrates, including
several involved in mitochondrial homoeostasis.
Despite the recent breakthroughs in our understanding of parkin
structure and activation, we still do not have a clear picture of how
the Ubl domain maintains the tertiary inhibited conformation of
wild-type parkin and how this inhibition is disrupted by phosphory-
lation of both the Ubl domain and ubiquitin to activate parkin. Since
many disease-causing mutations are localized to the Ubl domain,
understanding how the Ubl controls the inhibition of parkin at the
molecular level will likely be the key to developing activator thera-
peutic molecules that may be useful in treating the disease. In this
work, we set out to understand how the Ubl domain regulates parkin
function and how the phosphorylation signals impact parkin activ-
ity. We report here the 1.8 A˚ resolution crystal structure of human
parkin, complete with the Ubl domain. Our structural and biochemi-
cal analysis reveals that the interface between the Ubl and RING1
domains is crucial for parkin’s regulation by remotely altering the
arrangement of the RING0/RING1 interface, giving rise to a
compact conformation. Furthermore, we determine the 2.3 A˚
structure of active phosphomimetic (S65D) parkin, which reveals
a conformation closer to that of the truncated parkin structures.
Combining comprehensive thermodynamic, biophysical and
structural analyses, we find that the role of the Ubl domain is to
prevent parkin function in the absence of the phosphoubiquitin
signal. We show that phosphorylation of the Ubl domain opti-
mizes parkin for phosphoubiquitin binding at the interface
between the RING0 and RING1 domains and present an NMR-
derived model of the parkin–phosphoubiquitin complex. Further,
we identify that phosphoubiquitin binding leads to displacement
of the Ubl domain, revealing a ubiquitin recognition site used to
assist recruitment of the ubiquitin–E2 complex. These findings
establish a framework for understanding the cycle of parkin inhi-
bition and activation, provide a molecular rationale for the
observed E2 promiscuity and present a scaffold for targeting
domain–domain interactions to activate parkin.
Results
Although there are crystal structures of truncated parkin comprising
the RING0, RING1, IBR and RING2 domains (R0RBR parkin), and a
6.5 A˚ low-resolution structure of full-length parkin (Riley et al,
2013; Trempe et al, 2013; Wauer & Komander, 2013), there are no
high-resolution molecular details of parkin with the Ubl domain
intact. Given the importance of this domain, and observations
that ARJP mutations within this domain lead to increased ubiquiti-
nation activity (Chaugule et al, 2011), we aimed to identify the
molecular determinants of the autoinhibition. To re-affirm the
autoinhibitory role of the Ubl domain and to test the importance of
the linker, we conducted ubiquitination assays using an improved
fluorescence-based method (Fig 1A). These experiments repeatedly
showed that removal of the Ubl domain (77-C, 111-C) leads to
increased parkin autoubiquitination as well as formation of free
polyubiquitin chains that was enhanced upon stimulation with
phosphoubiquitin. In contrast, more complete removal of the linker
(127-C, 141-C (R0RBR)) appears to reverse this process leading to
similar ubiquitination levels as the wild-type protein, perhaps indi-
cating that the N-terminus of the linker may play an undiscovered
role in ubiquitination by parkin.
Attempts to crystallize the full-length protein did not generate
high-quality crystals, so we undertook a rational approach to
provide details of the Ubl domain interaction with the rest of the
protein. Previous work has shown that the linker region between
the Ubl and RING0 domains (residues 77–141) in parkin is likely
poorly structured with little known function (Hristova et al, 2009).
In addition, the linker is the most divergent region for parkin when
sequences are compared from multiple species (Fig EV1). This
suggested that careful deletion of the linker might improve crystal-
lization without eliminating the inhibitory functionality of the Ubl
domain. We generated a series of human parkin proteins with modi-
fied linker lengths (Fig 1B) between the Ubl domain and RING0-
RBR domain to test their ubiquitination activity and ability to form
high-quality crystals. In particular, one construct (UblR0RBR) that
included the Ubl (residues 1–83) linked to RING0RBR (residues
144–465) showed autoinhibition similar to the wild-type protein,
enhanced ubiquitination with phosphoubiquitin and the ability
to ubiquitinate a potential mitochondrial substrate protein, Miro1
(Kazlauskaite et al, 2014a) (Fig 1B).
The structure of parkin reveals a compact, autoinhibited
conformation
The crystal structure of UblR0RBR parkin was solved and refined to
1.8 A˚, and comprises two molecules in the asymmetric unit
(Table 1). The structure has five domains: Ubl (1–76), RING0 (144–
216), RING1 (228–327), IBR (328–377) and RING2 (415–465), and a
repressor element (REP) (Fig 1C). Residues 354 and 357–360 in the
IBR domain are missing in the density, as are the residues 383–390
linking the IBR to the REP, and residues 406–413 linking the REP to
the RING2 domain.
The position of the Ubl domain, located between the RING1 and
IBR domains, is globally consistent with the low-resolution 6.5 A˚
structure of full-length rat parkin (Trempe et al, 2013) (Appendix Fig
S1). The largest interface in the structure is that formed between the
Ubl domain and the rest of parkin, burying ~2,150 A˚2 accessible
surface area (Fig 2A). The primary contact is between the Ubl (b3,
b5) and RING1 (helix H1) domains (Fig 2A; Fig EV1). The core inter-
face is stabilized by hydrophobic interactions mediated by I44 and
V70 of the Ubl domain and L266, V269 and T270 of RING1 (Fig 2A).
This interaction is supported by several key salt bridges and hydro-
gen bonds including R42 (Ubl) with D262 at the N-terminus of helix
H1 (RING1) and R6 and H68 (Ubl) with N273 and D274 at the
C-terminus of helix H1. The tail of the Ubl domain is stabilized by
interactions between the main chain carbonyl oxygens of R75 and
K76 with R245 of RING1. In addition, N8 (Ubl) of the b1–b2 loop sits
between E310 and Q311 at the extreme N-terminus of the bent helix
(H3) connecting the RING1 and IBR domains (Fig 2A). There are few
contacts between the Ubl and IBR domains, the most obvious involv-
ing H11 (b1–b2 loop, Ubl) with P333 and K369 (IBR). The intimate
Ubl/RING1 association also occurs in trans, based on solution NMR
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Figure 1. Three-dimensional structure of UblR0RBR parkin.
A Ubiquitination assays show wild-type and UblR0RBR parkin are inhibited for chain formation (top) and Miro1 ubiquitination (bottom) in the absence of
phosphoubiquitin at zero time point and in the presence of phosphoubiquitin at 30 min. Removal of the inhibitory Ubl domain leads to parkin activation dependent
on the length of the linker preceding RING0. The middle panel shows a Coomassie-stained loading control. A non-specific, ATP-independent band is indicated (*).
B Ubiquitination assays show effects of varying length of the linker between the inhibitory Ubl domain and R0RBR, in the presence and absence of phosphoubiquitin. A
non-specific, ATP-independent band is indicated (*).
C Overall structure of UblR0RBR parkin depicting the Ubl domain (green), RING0 (blue), RING1 (magenta), IBR (black), REP (yellow) and RING2 (brown). Loops outside
domains are in cyan. Zinc atoms are represented as grey spheres. Two views are shown related by a 90° rotation in x.
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experiments where the Ubl domain was titrated into R0RBR parkin
(residues 141–465). The largest chemical shift changes in R0RBR
occur in residues in helix H1, and helix H3 in the RING1 domain
(Fig 2B). In addition, chemical shift changes occur for residues
A383, S384 and G385 in the tether region following the IBR domain
(Fig 2B) that is not observed in the crystal structure, indicating these
residues interact with the Ubl domain transiently. Reverse titration
experiments that monitored changes in 1H-13C HMQC spectra of the
Ubl domain upon R0RBR addition show the methyl groups of resi-
dues I2, I44, A46, L61, I66 and V70 have the largest changes, consis-
tent with I44 and V70 facing the RING1 domain as in the crystal
structure (Appendix Fig S2) and I2, A46, L61 and I66 facing the
tether. Taken together, these data indicate an extensive interface
between the Ubl domain and the RING1 domain of parkin that exists
both in cis and in trans, in solution and in the crystal.
The extent and nature of the Ubl/RING1 interface suggests it is
important for autoinhibition of parkin. Consistent with this, several
activating ARJP mutations occur in the Ubl domain including R42P,
A46P and R33Q (Chaugule et al, 2011). The R42P mutation would
disrupt the central salt bridge between R42 and D262 (Fig 2A). The
ARJP mutation of R33Q would abolish a long-range ionic interaction
with E370 in the IBR domain. Finally, mutation of A46P would
induce a loss of secondary structure in the loop that interacts with
the tether region (Appendix Fig S2). Weakening or destabilizing of
these interactions that maintain the Ubl position would lead to a
loosening of its tight interface with RING1. To test the importance of
this interface, we generated several Ubl domain mutants and
assayed them for activity (Fig 2C). In contrast to wild-type Parkin,
Ubl-interface mutants are more active for chain formation and ubiq-
uitination of Miro1 (Kazlauskaite et al, 2014a). Taken together,
these data show that disruption of the Ubl-RING1 interface leads to
constitutively active parkin.
Presence of the Ubl domain maintains a compact
RING0–RING1 interface
Several groups reported high-resolution crystal structures of parkin
R0RBR domains from human and rat, lacking the Ubl domain (Riley
et al, 2013; Trempe et al, 2013; Wauer & Komander, 2013). In order
to understand what conformational changes, if any, occur beyond
the Ubl/RING1 interface when the Ubl is present, we compared
UblR0RBR parkin with the truncated R0RBR structures. The struc-
tures agree well (Appendix Fig S3) with root mean squared dif-
ferences (rmsd) between 1.4 A˚ (rat R0RBR, 4K7D) and 1.8 A˚
(human R0RBR, 4I1F). The observed differences are due largely to
the positions of the IBR domains in each structure (Appendix Fig
S3). Heteronuclear nOe experiments show this domain exhibits the
greatest degree of flexibility of any domain in R0RBR parkin
(Appendix Fig S4). The REP is located in the equivalent position,
and the RING0/RING2 interface is maintained between structures
(Appendix Fig S3). Interestingly, when the structures are super-
imposed using the RING0/RING2 domains as the reference point,
the flexibility of the other domains is more pronounced (Fig 3A). In
particular, the RING0/RING1 interface widens in the absence of the
Ubl domain as the IBR domain swings ~12 A˚ away from its position
when the Ubl domain is attached. These global changes suggest a
pivot or hinge in parkin centred near the RING0/RING1 interface. In
UblR0RBR, the RING0/RING1 interface buries 730 A˚2 and involves
Y147, Y149, K151, Q155, V157, W183 and L187 of the RING0
domain interacting with H227, I229, A230, P247, E300, H302, R305,
I306 and E309 of the RING1 domain (Figs 3B and EV1). Comparison
of this interface in UblR0RBR with that in R0RBR reveals a number
of changes (Fig 3C). A salt bridge formed by R234 and E404 pinning
the domains together is absent in the R0RBR structure, but present
when the Ubl domain is attached. A hydrogen bond between H227
and E300 is observed in the presence of the Ubl domain, but not in
the R0RBR structures (Fig 3C). In the Ubl-bound structure, the side
chains of H302 and E300 (and H227) are facing into the interface,
while in the R0RBR structures, these residues are flipped out ~180°
away from the interface (Fig 3C). This latter conformation is
observed in all R0RBR structures, suggesting this is a consequence
Table 1. Crystallographic data collection and refinement statistics.
UblR0RBR S65DUblR0RBR
Wavelength (Å) 0.9174 0.9172
Resolution (Å) 56.36–1.79
(1.85–1.79)
23.16–2.37
(2.46–2.37)
Space group P212121 P212121
Unit cell abc (Å) abc (°) 67.3 67.3 206.2 90
90 90
66.3 66.3 205.6 90
90 90
Total reflections 276,440 216,582
Unique reflections 87,891 37,844
Multiplicity 3.1 (2.8) 5.7 (5.0)
Completeness (%) 98.8 (97.6) 99.8 (98.8)
Mean I/sigma(I) 11.2 (1.8) 7.7 (1.5)
Wilson B-factor (Å2) 30.7 46.0
R-merge 4.9 (56.5) 17.4 (116.9)
R-meas 6.7 (77.0) 19.1 (130.6)
CC1/2 99.6 (75.3) 99.3 (55.4)
Reflections for R-free 4,270 1,854
R-work 0.192 (0.224) 0.220 (0.241)
R-free 0.212 (0.227) 0.241 (0.267)
CC (work) 0.951 0.912
CC (free) 0.946 0.905
Number of non-hydrogen
atoms
6,943 6,424
Macromolecules 6,180 6,055
Ligands 52 56
Water 711 313
Protein residues 784 784
RMS bonds Å 0.008 0.007
RMS angles (°) 0.94 0.87
Ramachandran favoured
(%)
96.4 95.0
Average B-factor (Å2) 49.1 52.9
Macromolecules 48.2 53.0
Ligands 44.1 62.0
Water 57.3 49.6
Numbers in parentheses indicate outer shell statistics.
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of the absence of the Ubl domain, rather than an artefact of crystal
packing.
A negative charge at position 65 of the Ubl domain causes
remodelling of the RING1/RING0 interface
Phosphorylation of S65 in the Ubl domain enhances parkin activity
(Kondapalli et al, 2012). In order to understand what conformational
changes occur upon phosphorylation of the Ubl domain, we
attempted unsuccessfully to crystallize phosphorylated parkin.
Therefore, we crystallized a version of parkin carrying a negative
charge at position 65 (S65DUblR0RBR). This protein, as well as
S65EUblR0RBR, showed increased ubiquitination activity compared
to wild-type parkin that was further enhanced by phosphoubiquitin
in a similar fashion to phosphorylated UblR0RBR (Appendix Fig S5).
The S65DUblR0RBR crystals grew under the same conditions, with
the same unit cell dimensions and crystal packing, as the wild-type
UblR0RBR crystals, suggesting little or no structural changes. The
structure of S65DUblR0RBR parkin was refined to 2.4 A˚ (Table 1),
with the same residues present in the density as in the wild-type
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Figure 2. The molecular determinants of Ubl-mediated autoinhibition.
A Close-up of the Ubl/RING1 interface in parkin UblR0RBR in the same colours and orientation as Fig 1C bottom. Hydrogen bonds and salt bridges in the interface are
shown.
B Selected regions from 600 MHz 1H-15N TROSY spectra showing 200 lM 2H,13C,15N-labelled R0RBR (black contours) following the addition of 300 lM of the Ubl
domain (red contours). Residues shown that undergo chemical shift changes are F277 (RING1, helix H1), Y312 and Y318 (RING1, helix H3) and G385 (tether following
IBR domain and not visible in the crystal structure).
C Ubiquitination assays of Ubl domain mutants showing increased activity of interface mutants for both chain formation (top) and Miro1 ubiquitination (bottom), with
a Coomassie-stained loading control shown in between. Time points as in Fig 1A. A non-specific, ATP-independent band is indicated (*).
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UblR0RBR crystals. Superposition of S65DUblR0RBR and UblR0RBR
(rmsd 0.58 A˚) reveals no global conformational changes either in the
Ubl domain, or in other parts of the protein (Fig 3D). However, close
inspection reveals that H227, E300 and H302 of the RING0/RING1
interface are remodelled in the S65DUblR0RBR structure to resemble
the interface observed in the truncated R0RBR structures (Fig 3E).
Interestingly, the remodelling of these residues gives rise to a contin-
uous basic patch comprising K151, H302 and R305 on the surface of
H227
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Figure 3. The RING0/RING1 interface is a hinge that remodels upon parkin phosphorylation.
A Overlay of UblR0RBR (coloured according to Fig 1C) and R0RBR (grey) structures. Absence of the Ubl domain causes a hinge opening at the RING0/RING1 interface.
B Close-up of the RING0/RING1 interface in UblR0RBR showing key residues that are involved in ionic/hydrogen bond interactions.
C Overlay of the RING0/RING1 interface from UblR0RBR (coloured) and R0RBR (grey). Green dashes show distances in Å between residues in UblR0RBR, and red dashes
show distances between residues in R0RBR.
D Structure of S65DUblR0RBR (pink) overlaid with UblR0RBR parkin (coloured according to Fig 1C). The position of D65 or S65 is shown in inset.
E Comparison of the hinge in UblR0RBR (left), S65DUblR0RBR (middle) and R0RBR (right).
F Surface of UblR0RBR (left) and S65DUblR0RBR (right) showing continuous basic patch formed by hinge opening.
G Ubiquitination assays of mutations in the RING0/RING1 interface. Mutations in residues that pin H302 in the flipped-in position are activating, mutation of the basic
patch prevents parkin activity, even in the presence of increasing concentrations of phosphoubiquitin (+). This is the case for both chain formation (top) and Miro1
ubiquitination (bottom). A Coomassie-stained loading control is shown in between. A non-specific, ATP-independent band is indicated (*).
The EMBO Journal ª 2015 The Authors
The EMBO Journal Inhibition and activation of parkin Atul Kumar et al
6
Published online: August 7, 2015 
Parkin, which is not present when the Ubl domain is unmodified
(Fig 3F). Since parkin ubiquitination activity is further enhanced
through phosphoubiquitin binding, we hypothesized that this basic
patch is the phosphoubiquitin-binding site. To test this, we generated
H302A parkin and assayed this for interaction with phosphoubiqui-
tin (pUb) (Appendix Fig S6). In contrast to wild-type parkin, H302A
parkin does not bind pUb. Furthermore, mutation of residues at the
top of the interface that pin the E300 and H302 in the flipped-in
conformation is more active than wild-type parkin, while mutation
of the residues in the basic patch displays diminished activity
compared to wild-type, and cannot be stimulated with pUb (Fig 3G).
Taken together, these data suggest that the addition of a negative
charge at position 65 of the Ubl domain alters the surface of parkin
at the RING0/RING1 interface to facilitate optimal pUb binding.
Phosphorylated ubiquitin binding induces a structural change
in parkin
PINK1-mediated phosphorylation of ubiquitin at S65 (pUb)
enhances parkin activity. In order to understand how this is
achieved, we performed chemical shift perturbation experiments
monitored by 1H-15N TROSY spectroscopy. Addition of pUb to
C pUbl + R0RBR pUb + R0RBR
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Figure 4. Mechanism of phosphoubiquitin binding and conformational change in parkin.
A Chemical shift perturbation map of R0RBR upon the addition of pUb. A colour gradient is used to show residues and the corresponding surface with little or no
changes (grey) and scaled from light pink (average chemical shift change) to magenta (greater than average + 2 standard deviations). Parkin is shown as a
transparent surface over a ribbon, and the orientation of the molecule is similar to that shown in Fig 1C (bottom).
B Representative model of pUb interaction with parkin derived from HADDOCK calculations using chemical shift perturbation and paramagnetic relaxation
enhancement experiments. One hundred water-refined structures were calculated that all showed a similar pUb orientation. The best twenty complexes showed
excellent agreement (backbone rmsd 0.37 Å, pUb + R0RBR). The model shown has been rotated 90° (x) and 20° (y) with respect to Fig 1C (top). The colours used are
the same as in Fig 1C with pUb shown in orange. The pS65 is shown as red sticks, and the basic triad consisting of K151, H302 and R305 are shown as blue sticks.
Several important residues that had significant chemical shift changes in pUb upon R0RBR interaction are indicated.
C Representative isothermal titration calorimetry experiments showing the exothermic binding of pUbl to R0RBR parkin (left) and endothermic binding of pUb to
R0RBR parkin (right).
D Bar graph showing the thermodynamic properties for Ubl, pUbl, Ub and pUb binding to R0RBR. The data show Ubl binding and pUbl binding are driven by enthalpy
(DH) changes, while Ub binding and pUb binding are driven by entropy changes (DS) indicative of a pUb-induced conformational change.
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R0RBR results in a cluster of residues with significant chemical shift
changes including Y149, C150, K151 and G152 (RING0); R275,
F277, V278, D280, Q282, G284, Y285 and S286 (b16–b17 in
RING1); and I306, G308, E309, Y312 and N313 (helices H2, H3 in
RING1) (Fig 4A; Appendix Fig S7). These residues surround the
hinge region at the RING0/RING1 interface that is optimized for
pUb binding (Fig 3B, C, E and F). There are no significant chemical
shift changes in the RING2 domain or RING0/RING2 interface
(Fig 4A), indicating that pUb binding does not alter the interface
between these two domains that includes the catalytic cysteine.
These data reinforce that the hinge region at the RING0/RING1
interface is the pUb-binding site. Using these chemical shift pertur-
bation experiments, we generated a model of parkin in complex
with pUb (Fig 4B) using HADDOCK. The orientation of the pUb
with respect to parkin was confirmed by using paramagnetic relax-
ation enhancement experiments with a spin label covalently
attached to either L8C-pUb or K48C-pUb and observing residues
with signal intensity changes in parkin in 1H-15N TROSY spectra.
In the model, pUb sits across a V-shaped cavity formed at the
RING0/RING1 hinge region (Fig 4B). The basic triad, K151-H302-
R305, surrounds the phosphoSer65 of ubiquitin. The pUb orienta-
tion is governed by the b1–b2 loop in pUb that interacts with
residues on the bent helix H3 of the RING1 domain and residues
in the adjacent IBR domain. The C-terminal tail of pUb including
residues V70 and L71 runs parallel to helix H3 of the RING1
domain. In addition, residues in the b3–b4 region of pUb (I44,
A46) intercalate between strands b16–b17 and helix H3 of the
RING1 domain. It is interesting that one component for pUb recog-
nition, the short b16–b17 region in RING1, appears to be absent in
all other RING domain protein structures. Further, the position of
the b16–b17 loop is absent in the structure of the RBR E3
ligase HHARI (Duda et al, 2013) where it is replaced by a
ubiquitin-associated like domain. The pUb-binding site is remote
from the typical E2-binding site expected to reside on the opposite
end of the RING1 domain.
Since the crystal structures of UblR0RBR and NMR titration
experiments show that the RING0/RING1 interface is altered upon
Ubl binding, we hypothesized that a similar allosteric event might
occur through pUb binding to parkin. Consistent with this, several
chemical shift changes occur in residues at the junction of the
C-terminus of helix H3 and the IBR domain upon pUb addition
(Fig 4A). The isolated IBR domain shows no chemical shift pertur-
bations when S65EUb is titrated in, suggesting the chemical shift
changes at the helix H3/IBR domain interface might result from a
structural change that accompanies pUb binding. In order to test
this, we used isothermal titration calorimetry (ITC) to measure
thermodynamic changes in enthalpy (DH) and entropy (DS) that
occur upon binding of R0RBR with pUb, S65DUb or S65EUb (Fig 4C,
Table 2). As a control, we measured the binding of pUbl and
phosphomimetic Ubl domains to R0RBR where remodelling of the
RING0/RING1 interface is the most notable structural change. As
expected from the crystal structures, pUbl interacts exothermically
with R0RBR with negative enthalpy (16 kJ/mol) and small entropy
(33 J/mol˚K) changes consistent with new ionic and hydrophobic
interactions formed and minimal overall structural change (Fig 4C
and D). The data also show that Ubl binding to R0RBR is enthalpi-
cally driven regardless of whether the phosphomimetics (S65DUbl,
S65EUbl) or pUbl is used, indicating the phosphomimetic Ubl and
pUbl proteins have similar binding modes to R0RBR. Remarkably,
the interaction of pUb or phosphomimetic ubiquitin (S65DUb,
S65EUb) with R0RBR, or pUb with full-length parkin, has opposite
enthalpy and entropy changes (Fig 4C and D, Table 2). In contrast
to Ubl binding, the binding of pUb to R0RBR is an endothermic
binding event marked by large positive enthalpy (+32 kJ/mol) and
Table 2. Thermodynamic properties for parkin activation.
Protein Activator Kd (lM) N ΔH (kJ/mol) ΔS (J/molK)
A. R0RBR Parkin with Ubl and Ub
R0RBR Ubl 3.8  1.3 0.98 44  3 44
Ubl S65D 5.0  0.9 1.03 38  1 29
Ubl S65E 5.3  1.2 0.98 46  2 54
pUbl 26  10 1.04 16  9 33
R0RBR Ub 67  1.0 1.05 31  1 184
Ub S65D 6.6  0.3 1.01 25  1 184
Ub S65E 6.6  0.1 1.10 48 261
pUb 0.016  0.002 0.93 32 261
B. Full-length Parkin with Ubl and Ub
Parkin Ubl N.O. – – –
Ub 45  9 0.90 10  1 115
pUb 0.16  0.02 1.09 50 293
0.37  0.04a – – –
pParkin pUb 0.021  0.006
0.017  0.005a – – –
Average values from a minimum of two experiments.
aData from Ordureau et al (2014).
N.O.,binding not observed.
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entropy (+261 J/mol˚K) changes (Fig 4C and D). The large positive
entropy change signifies that the pUb–R0RBR interaction is driven
by an increase in disorder in the system, a result of a loss of struc-
ture in parkin that accompanies pUb binding (Fig 4C). Interestingly,
three-dimensional structures of the isolated IBR domain show little
structure in the region that comprises the C-terminus of helix H3 of
the RING1 domain, the site of several chemical shift changes upon
R0RBR interaction with pUb (Beasley et al, 2007). This is in contrast
to the crystal structures (Fig 1C) that show a well-defined, albeit
bent helix that interacts with the first Zn2+-binding site of the IBR
domain and the C-terminus of helix H1 in the RING1 domain.
Together, these data show that pUb binding to the RING0/RING1
hinge interface results in a concomitant loss of structure near the
C-terminus of helix H3 (RING1) and the IBR domain.
Phosphorylated ubiquitin binds to parkin and displaces the
Ubl domain
Our crystallographic studies show that phosphorylation of the Ubl
domain optimizes the RING0/RING1 interface for pUb binding,
while NMR and ITC experiments show pUb binding causes a loss of
structure near the IBR domain. These allosteric structural changes
infer that pUbl and pUb cannot be bound to parkin simultaneously.
In order to test this, we performed a competition experiment
monitored by NMR spectroscopy. We titrated R0RBR parkin
into 13C-labelled S65EUbl (Fig 5A, top) and followed this in
1H-13C-HMQC spectra such that signals from both the unbound and
bound forms of S65EUbl were visible. For example, changes in the
positions of A46 and L61 of the Ubl domain show a clear interaction
with R0RBR. Upon addition of S65EUb, the signals for the bound
form of S65EUbl revert back to those of the unbound S65EUbl state
(Fig 5A, bottom). This experiment shows that phosphomimetic Ub
binding displaces the bound S65EUbl domain from parkin. In a
reciprocal experiment, we titrated R0RBR parkin into 13C-labelled
S65EUb to form the activated R0RBR–S65EUb complex (Fig 5B,
top). Upon addition of S65EUbl, the signals for the bound form of
S65EUb remain (Fig 5B, bottom) despite S65EUb and S65EUbl
having similar dissociation constants for R0RBR (Table 2). This
indicates that phosphomimetic Ubl domain is unable to bind to an
activated R0RBR–S65EUb complex. Together, these experiments
show that simultaneous binding of S65EUbl and S65EUb to R0RBR
is not possible. Further, the data show that although S65EUbl opti-
mizes the pUb-binding site, the binding of S65EUb fully releases
S65EUbl from parkin, consistent with the proposed allosteric loss of
structure to the C-terminus of helix H3 and IBR domain that would
interfere with the Ubl-binding site. This would also indicate that acti-
vation of parkin through pUb binding would prevent re-engagement
with the Ubl domain until the pUb is released.
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Figure 5. pUb binding displaces the Ubl domain.
A (Top) Selected regions of 1H-13C HMQC spectra for 150 lM 13C-labelled S65EUbl (black contours) following the addition of one equivalent of unlabelled R0RBR parkin.
Approximately 83% of the S65EUbl is bound to R0RBR parkin (orange contours) based on a Kd = 5 lM (Table 2). The arrows show the position of the bound
13C-
labelled S65EUbl signal upon R0RBR binding. (Bottom) The same sample and regions following the addition of 150 lM unlabelled S65EUb show the disappearance of
most of the bound 13C-labelled S65Ubl-R0RBR species and re-appearance of unbound S65EUbl (red contours), indicating S65EUb is able to displace S65EUbl.
B (Top) Selected regions of 1H-13C HMQC spectra for 13C-labelled S65EUb (black contours) following the addition of one equivalent of unlabelled R0RBR parkin (orange
contours). Boxes show the position of the bound 13C-labelled S65EUb signal upon R0RBR binding visible at lower contour levels. (Bottom) The same sample following
the addition of one equivalent unlabelled S65EUbl shows no change in the intensities and position of the bound 13C-labelled S65EUb (red contours), indicating that
S65EUbl is unable to bind to R0RBR in the presence of S65EUb.
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Activation by phosphoubiquitin uncovers a ubiquitin
recognition site
The residues involved in the Ubl/RING1 interface are largely
conserved between ubiquitin and the Ubl domain (Fig 6A and B).
Thus, displacement of the Ubl domain by phosphoubiquitin bind-
ing may lead to exposure of a surface competent for interaction
with ubiquitin. We and others have previously reported an interac-
tion between active parkin and ubiquitin (Chaugule et al, 2011;
Zheng & Hunter, 2013). Therefore, we wondered if the conse-
quence of Ubl displacement is to provide a ubiquitin-binding
surface for recruitment of the charged E2~ubiquitin complex. In
order to test this hypothesis, we generated mutations in helix H1
of the RING1 domain and assayed them for ubiquitin chain forma-
tion and Miro1 ubiquitination. Single-point mutations D262A,
T270R and D274R are deficient in both ubiquitin chain formation
and Miro1 ubiquitination (Fig 6C), in contrast to corresponding
Ubl domain mutations that are activating (Fig 2C). Interestingly,
the single L266K mutant is active for ubiquitin chain formation
but deficient in Miro1 ubiquitination. This suggests that although
L266K would be expected to repel the Ubl domain, it is still able
to form a productive complex with the E2~Ub. In contrast, a triple
mutant along the Ubl-binding surface of helix 1, D262A/L266K/
D274R, is unable to form ubiquitin chains or ubiquitinate Miro1
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Figure 6. pUb binding to parkin uncovers a ubiquitin binding site.
A Structure-based alignment of Ubl domain and ubiquitin. Conserved residues are shown in green, and conservative substitutions are shown in blue. Residues that
interact with the RING1 domain (magenta), IBR (black) and tether (cyan) are denoted with circles.
B Close-up of the interface between helix H1 in the RING1 domain and the Ubl domain based on the structure shown in Fig 1C. Key residues for the interaction are
highlighted. The structure of ubiquitin is superimposed with Ubl domain including the corresponding residues found at the RING1 interface.
C Ubiquitination assay of RING1 mutations in the Ubl/RING1 interface. Effects of single-point mutations and a triple mutation on both ubiquitin chain formation (top)
and Miro1 ubiquitination (bottom) are shown. A Coomassie-stained loading control is shown in between. A non-specific, ATP-independent band is indicated (*).
D Size-exclusion chromatography of phosphoparkin (pParkin), phosphoparkin and phosphoubiquitin (pUb), phosphoparkin, phosphoubiquitin and UbcH7, and
phosphoparkin, phosphoubiquitin and UbcH7 isopeptide linked to ubiquitin (UbcH7~Ub) (left) versus the same experiment using the triple mutant of parkin (right). A
coloured key of each trace is provided, and Coomassie-stained gels of the indicated peaks are shown below the trace.
E Isothermal titration calorimetry of phosphoparkin complexed with phosphoubiquitin titrated with either UbcH7 alone (left) or UbcH7~Ub (right). Dissociation
constants for each titration are shown.
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(Fig 6C). Recent data suggest that in the presence (but not
absence) of phosphoubiquitin, parkin forms a discrete complex
with E2~Ub (Ordureau et al, 2015). Therefore, we assayed the
ability of the wild-type phosphoparkin/phosphoubiquitin complex
to interact with E2, or E2~Ub (Fig 6D). Phosphoparkin and phos-
phoubiquitin form a complex as measured by size-exclusion chro-
matography consistent with the tight binding observed in ITC
experiments (Table 2). Addition of the E2 UbcH7 does not produce
a further shift consistent with the observed moderate binding
affinity of UbcH7 for phosphoparkin in the presence of phospho-
ubiquitin (Kd = 19 lM, Fig 6E). In contrast, the addition of
UbcH7~Ub leads to the formation of a higher molecular weight
complex that has an apparent 20-fold tighter affinity than UbcH7
alone (Fig 6D and E), suggesting the ubiquitin molecule is recog-
nizing an additional binding site on parkin. To test whether
this ubiquitin site includes the D262/L266/D274 residues along
helix 1, similar size-exclusion chromatography experiments were
conducted using the D262A/L266K/D274R triple mutant protein.
In contrast to wild-type parkin, the RING1 triple mutant is unable
to form the pParkin/pUb/UbcH7~Ub complex (Fig 6D). Taken
together, these data suggest that the consequence of Ubl displace-
ment is the creation of a ubiquitin-binding site on RING1 to facili-
tate E2~Ub recruitment.
Discussion
Until 2011, parkin was thought to be constitutively active. Since
then, it has become clear that parkin is regulated in multiple ways.
The Ubl domain inhibits parkin activity (Chaugule et al, 2011), the
REP element blocks an E2-binding site (Trempe et al, 2013), and it
has been proposed that the catalytic cysteine, C431, is occluded by
the RING0 domain (Riley et al, 2013; Trempe et al, 2013; Wauer &
Komander, 2013). An important observation from the structures of
UblR0RBR and S65DUblR0RBR parkin is that the catalytic cysteine
(C431) in the RING2 domain remains in a similar environment as
that found in truncated parkin structures lacking the Ubl domain.
Further, NMR chemical shift perturbation experiments show
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(1) Inhibition: Wild-type parkin is autoinhibited in the absence of phosphoubiquitin. PINK1 activation leads to phosphorylation of the accessible S65 in both parkin and
ubiquitin. (2) Optimization: Parkin phosphorylation stabilizes the flipped-out conformation of H302, thus optimizing the phosphate-binding site. (3) Release:
Phosphoubiquitin binds to helix H3 of the RING1 domain, leading to displacement of the Ubl domain and loss of structure near the RING1/IBR interface. (4) Engagement: The
ubiquitin and E2 binding surfaces uncovered by displacement of the Ubl domain engage with charged E2~Ub conjugate poised for ubiquitin transfer.
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minimal changes for C431 or to residues at the RING0/RING2 inter-
face near the catalytic site, indicating this region of parkin does not
undergo any large structural change that might expose C431. Inter-
estingly, analysis of the UblR0RBR, S65DUblR0RBR and R0RBR
structures all show the thiol group of C431 is partially exposed and
capable of accepting a ubiquitin molecule from the E2~Ub conju-
gate. Thus, the increased ubiquitination reactivity observed upon
phosphoubiquitin binding likely results from enhanced recruitment
of the E2~Ub conjugate due to exposure of an E2~Ub-binding site
following release of the Ubl domain (Fig 6), rather than a change in
structure near the catalytic C431 site.
The discovery of autoinhibition propelled efforts to uncover acti-
vators of parkin, the most compelling of which is the kinase, PINK1,
upstream of parkin (Clark et al, 2006; Park et al, 2006). PINK1
phosphorylates the Ubl domain and ubiquitin at the equivalent
residue S65, leading to parkin activation (Kondapalli et al, 2012;
Kane et al, 2014; Kazlauskaite et al, 2014b; Koyano et al, 2014).
Recent studies report effects of each phosphorylation signal on the
activity of parkin. For example, while parkin can be phosphorylated
by PINK1 in the absence of phosphoubiquitin, the addition of pUb
enhances parkin phosphorylation, suggesting that parkin bound to
pUb is a better substrate for PINK1 than parkin alone (Kazlauskaite
et al, 2015). However, phosphorylation of parkin is independent of
parkin catalytic activity and parkin associates tightly with ubiquitin
chains only when both ubiquitin and parkin are phosphorylated
(Ordureau et al, 2014), leading to the proposal of a feed-forward
mechanism. Furthermore, in cells where the only ubiquitin source is
a non-phosphorylatable S65A mutant, parkin is still phosphorylated
(Ordureau et al, 2015), albeit GFP-tagged parkin, which is an impor-
tant caveat since it is not established that N-terminally tagged parkin
species can be interpreted as wild-type (Chaugule et al, 2011;
Burchell et al, 2012). We present here a mechanistic model of
parkin inhibition and allosteric activation based on our structural,
biochemical and biophysical insights (Fig 7). First, the Ubl domain
inhibits parkin activity in the absence of phosphoubiquitin signal
(Fig 7, step 1). In this inhibited conformation, the E300 and H302
are facing into the RING0/RING1 interface. Upon activation, PINK1
phosphorylates ubiquitin and the Ubl domain of parkin (Fig 7, step 2)
to induce a remodelling of the RING0/RING1 interface (Fig 3C–E).
Although phosphorylation of ubiquitin alone leads to a dramatic
increase in its affinity for parkin (Table 2, Fig 4D), this optimized
parkin conformation exhibits a further 10-fold greater affinity for
pUb (Ordureau et al, 2014) (Table 2) mediated by the H302/R305/
K151 basic patch (Fig 7, step 3, Fig 3B). Our model of the pUb-bind-
ing site along helix H3 of RING1 is confirmed by the recent crystal
structure of pUb bound to Pediculus humanus R0RBR parkin
(Wauer et al, 2015). Phosphoubiquitin binding leads to an entropi-
cally driven loss of structure in the RING1 bent helix (H3) (Fig 7,
step 3). This remodelling leads to release of the Ubl domain,
exposing the binding surface on RING1. Since the residues in the
Ubl domain that bind the RING1 domain are well conserved with
ubiquitin (Fig 6A and B), our model predicts that this exposed
RING1 surface will engage ubiquitin in an E2~Ub conjugate to
form a ‘charged’ parkin (Fig 7, step 4). This accounts for observa-
tions that parkin can function with different E2s. Finally, the
tightly associated inhibited structure, small conformational
changes, interface remodelling and multiple binding sites explain
why different patient mutations have different effects on parkin
activity. Although there is some debate on the ‘order’ of activating
events, our study supports a model whereby each phosphorylation
event enhances the activation of parkin, which is likely a major
mechanism of parkin regulation in the context of low concentra-
tions of pUb in cells (Koyano et al, 2014). The mechanistic model
presented here provides important insights into parkin regulation
that will be key to designing therapeutics that can control the
activity of parkin and may be useful in the treatment of early-
onset forms of Parkinson’s disease.
Materials and Methods
Protein purification and crystallization
UblR0RBR Parkin (residues 1–83, 144–465), phosphomimetic
S65DUblR0RBR and R0RBR (residues 141–465, lacking Ubl
domain and linker) constructs were expressed as His-Smt3 fusion
proteins in BL21 E. coli cells as previously described (Chaugule
et al, 2011; Spratt et al, 2013). Media were supplemented with
50 lM ZnCl2, and cells were induced at 0.6 OD600 with 120 lM
of isopropyl b-D-1-thiogalactopyranoside (IPTG) and incubated
overnight at 16°C. Cells were lysed, and protein was purified over
Ni-NTA resin. Beads were incubated overnight at 4°C with ULP1
protease to remove the His-Smt3 tag. The flow through from Ni-
NTA incubation was collected and passed through a Mono-Q
column and then loaded on Superdex-75 equilibrated with Buffer
A (20 mM Tris pH 7.5, 75 mM NaCl and 250 lM TCEP). Frac-
tions containing purified protein were pooled and concentrated
using Viva spin 10-kDa cut-off concentrators. UblR0RBR (6 mg/
ml) and S65DUblR0RBR (2.8 mg/ml) parkin were used for sitting
drop crystallization using commercial screens. Protein crystals
were obtained for both parkin forms at 4°C using 200 mM LiSO4,
100 mM BIS-TRIS pH 5.5 and 20% PEG 3350 by sitting drop
vapour diffusion method. Crystals appeared in 2–3 days and then
allowed to grow for a week. Crystals were flash-frozen using
20% glycerol as cryoprotectant. Native data sets were collected at
Diamond Light Source, beamline IO4-1 and IO4.
Synthesis and purification of phosphorylated ubiquitin and
Ubl domain
Pediculus humanus GST-PINK1 (128-C) was purified on a GSTrap
FF column (GE Healthcare) using 50 mM Tris, 250 mM NaCl, 1 mM
DTT at pH 7.5 and eluted with freshly prepared 50 mM Tris,
250 mM NaCl, 1 mM DTT and 10 mM glutathione at pH 7.5. GST-
PINK1 (10 lM) was incubated with either Ub (500 lM) or UblD
(500 lM) and dialysed against buffer containing 50 mM Tris,
0.5 mM DTT, 10 mM MgCl2 and 5 mM ATP (pH 7.5) for 2 h at
25°C. The reaction was monitored to completion using Phos-TagTM
SDS–PAGE. Following the reaction, GST-PINK1 was removed from
the reaction using a GSTrap FF column, collecting the flow-through
fractions containing pUb or the pUbl domain. The phosphorylated
proteins were separated from unphosphorylated species on a HiTrap
Q column using 20 mM Bis-Tris propane (pH 8.7) and a 2-h
0–100% 0.5 M NaCl elution gradient. Unphosphorylated species
were found in the flow through, while pure pUb and pUblD eluted
around 20–40% of the salt gradient.
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Synthesis and purification of UbcH7~Ub
The isopeptide-linked UbcH7~Ub conjugate was synthesized follow-
ing the method of Plechanovova et al (Plechanovova et al, 2012).
His-tagged Uba1 (25 lM, not TEV-cleavable), His-TEV-Ub (200 lM)
and UbcH7 (C17S/C86K/C137S, 400 lM) were incubated at 37°C for
up to 16 h in 50 mM CHES, 150 mM NaCl, 10 mM ATP and 10 mM
Mg2+ at pH 9.0 until UbcH7~Ub conjugate formation reached a
stable level as viewed by SDS–PAGE electrophoresis. Purification of
the UbcH7~Ub conjugate was performed with a HisTrap column
(GE Healthcare) initially to remove UbcH7, and following TEV
cleavage to remove His-Uba1. Purified UbcH7~Ub was isolated
using a HiLoad Superdex (GE Healthcare) size-exclusion column to
separate UbcH7-Ub from Ub.
Structure determination
Data were indexed, processed and scaled using Mosflm and Scala
as implemented in CCP4 (CCP4, 1994). The UblR0RBR structure
was determined by molecular replacement. Full-length rat parkin
structure (4K95) was used as a search model. The initial model
was further built and refined using coot (Emsley & Cowtan, 2004)
and autobuster (Bricogne et al, 2011). The phosphomimetic
S65DUblR0RBR structure was solved using UblR0RBR as the search
model, and refined as UblR0RBR. Both models have excellent
geometry with statistics listed in Table 1.
Isothermal titration calorimetry
All calorimetry experiments were performed using either a Microcal
VP-ITC system (GE Healthcare) or a NanoITC (TA Instruments) at
25°C. All experiments were completed 2–3 times using freshly
prepared proteins in either 50 mM HEPES, 50 mM NaCl and
250 lM triscarboxyethylphosphine (TCEP) at pH 7.5 or 50 mM
HEPES, 150 mM NaCl and 0,5 mM TCEP at pH 8.0. The concentra-
tions of each protein in the experiments were as follows: 50 lM
R0RBR parkin titrated with 1.25 mM ubiquitin, 750 lM S65D ubiq-
uitin, 400 lM phosphoubiquitin, 750 lM Ubl domain and 1 mM
phosphoUbl domain. Full-length parkin (50 lM) was titrated with
1.75 mM ubiquitin, 1.75 mM S65D ubiquitin or 400 lM phospho-
ubiquitin. Phosphoparkin (50 lM) was titrated with 400 lM phos-
phoubiquitin. Phosphoparkin (35 lM) was titrated with 2.4 lM
UbcH7 or UbcH7~Ub. Data were analysed using single-site binding
models.
Ubiquitination assays
Ubiquitination reactions were performed at 30°C in 50 mM DL-malic
acid, MES monohydrate, Tris (MMT) pH 7.5, 50 mM NaCl, 2.5 mM
MgCl2, 5% (v/v) glycerol and 0.75 mM dithiothreitol (DTT) buffer
system. All reactions contained 25 nM of recombinant human E1,
500 nM of UbE2L3 (UbcH7), 1 lM E3 and 5 mM ATP in a 20 ll
final reaction volume.
Complete ubiquitination profiles were analysed using fluores-
cently labelled ubiquitin (UbIR800). Ubiquitin (residues 2–76) was
expressed and purified bearing a GPLCGS overhang at the N-terminus.
The cysteine residue in the overhang was targeted for site-specific
incorporation of a DyLightTM 800 Maleimide (Life Technologies,
46621) dye following the manufacturer’s protocol. Labelled species
were purified by cation exchange chromatography and stored at
20°C as single-use aliquots. Reactions to monitor ubiquitination
profiles contained 2 lM of UbIR800 and supplemented with either
phosphorylated ubiquitin or unlabelled ubiquitin as indicated.
Reactions were terminated with SDS loading buffer, resolved by
SDS–PAGE and analysed by direct fluorescence monitoring using
Li-COR Odyssey Infrared Imaging System.
Glutathione S-transferase (GST)-human Miro1 (residues 1 to 592)
was expressed and purified using standard protocols. GST-Miro1
ubiquitination reactions were carried out as above except with a final
ubiquitin concentration of 20 lM (inclusive of indicated amount
phosphorylated ubiquitin). Reactions were subjected to immunoblot-
ting using anti-GST rabbit monoclonal primary antibody (1H14L28,
Life Technologies, 1/3,000 dilution) and fluorescent-labelled
secondary antibody (926-32213, Li-COR, 1/10,000 dilution). Blots
were visualized using Li-COR Odyssey Infrared Imaging System.
Size-exclusion chromatography–multiAngle light
scattering analysis
Size-exclusion chromatography and multiangle light scattering
(SEC–MALS) experiments were performed on a Dionex Ultimate
3000 HPLC system with an inline Wyatt miniDAWN TREOS MALS
detector and Optilab T-rEX refractive index detector. SEC–MALS
experiments were performed on a Superdex S75 CL 10/300 (GE
Healthcare) column in buffer containing 50 mM HEPES with
100 mM NaCl at pH 7.5. Phosphoubiquitin (140 lM) and phospho-
parkin proteins (20 lM) were incubated for 30 min before injec-
tions. Molar masses spanning elution peaks were calculated using
ASTRA v6.0.0.108 (Wyatt). For the size-exclusion analysis with
UbcH7 or UbcH7~Ub, phosphoparkin proteins (20 lM) were incu-
bated with phosphoubiquitin (40 lM) and either UbcH7 (40 lM) or
UbcH7~Ub (40 lM) for 30 min prior to injections.
NMR spectroscopy
Uniformly 2H,13C,15N-labelled or 2H,12C,15N-labelled parkin R0RBR
was expressed in minimal media supplemented with 15NH4Cl (1 g)
and either 2H,13C-glucose (2 g) or 2H,12C-glucose (2 g)(Cambridge
Isotope Laboratories). Cells were initially grown in 70% D2O until
the OD600 reached 0.9 units. Cells were pelleted, re-suspended in
minimal media containing 99.8% D2O supplemented with 0.25 mM
ZnCl2 and grown until the OD600 reached 0.8 units. Following the
addition of a further aliquot of ZnCl2 (0.25 mM), the temperature
was lowered to 16°C and cells were induced with 100 lM IPTG for
20 h. Assignment of R0RBR was accomplished using 2H,13C,15N-
labelled protein (300–500 lM) in 25 mM HEPES, 100 mM NaCl,
0.5 mM TCEP and 90% H2O/10% D2O at pH 7.0 using DSS as an
internal reference. All NMR data were collected at 25°C on a Varian
Inova 600 MHz NMR spectrometer equipped with a triple resonance
cryogenic probe and z-field gradients or an 850 MHz Bruker Avance
III spectrometer with TCI cryoprobe. All 1H,15N-HSQC spectra were
collected in TROSY mode (Pervushin et al, 1997). Triple resonance
pulse sequences (HNCA, HN(CO)CA, HN(CA)CB, HN(COCA)CB,
HNCO, HN(CA)CO) (Yang & Kay, 1999) were collected in TROSY
mode using deuterium decoupling as described for fully deuterated
proteins. Heteronuclear NOE NMR experiments (Farrow et al, 1994)
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were performed at 600 MHz using 500 lM uniformly deuterated
parkin 141-C. Proton saturation was achieved through a 5-s irradia-
tion following an 11-s relaxation delay. The equivalent non-saturated
experiment contained a 16-s relaxation delay. Both saturated and
non-saturated experiments were conducted in duplicate. All data
were processed using NMRPipe and NMRDraw (Delaglio et al, 1995)
and analysed using NMRViewJ (Johnson & Blevins, 1994).
Protein interaction experiments were conducted using 100–
200 lM 2H,12C,15N-labelled R0RBR and either 13C-labelled or
2H,13C-labelled Ub or UblD proteins. 1H,15N-TROSY spectra were
collected to monitor chemical shifts of backbone amides in R0RBR.
1H,13C-HMQC spectra (Tugarinov et al, 2004) were collected to
monitor chemical shifts of side chain methyl groups in Ub or UblD.
Chemical shift perturbations were quantified using the following
weighted formula: ((0.2 × DdN2) + DdH2)1/2 and plotted as a func-
tion of residue using Prism5 (Graphpad).
Molecular modelling of phosphoubiquitin bound to parkin R0RBR
Docking of pUb with R0RBR used chemical shift perturbations from
NMR experiments (described above). Interacting residues in R0RBR
were defined as those that shifted greater than the average shift +
0.5 standard deviations and had greater than 20% side chain acces-
sible surface area. Due to the limited number of methyl-containing
residues, residues in pUb were chosen where methyl resonances
shifted regardless of accessible surface area. An upper distance limit
of 5.0 A˚ was set for ambiguous distance restraints. A single unam-
biguous distance restraint of 3.0 A˚ was set based on mutagenesis
experiments that indicated pS65 (Ub) was near H302 (R0RBR) that
was also supported by chemical shift changes of neighbouring resi-
dues. The coordinates for S65DUblR0RBR was used as the starting
structure following removal of the coordinates corresponding to the
Ubl domain and adjoining linker region. Missing regions, where
chemical shift changes were observed upon pUb interaction, were
modelled in using the Modeller (Eswar et al, 2006) plug-in for UCSF
Chimera (Pettersen et al, 2004). Docking of pUb with R0RBR used
HADDOCK (Dominguez et al, 2003). A total of 1,000 initial
complexes were calculated, and the best 100 structures were water
refined. Standard parameters were used except inter_rigid (0.1)
which was set to allow tight packing of the two proteins, and the
unambiguous force constants were increased by five-fold compared
to the unambiguous constants. The location and orientation of the
pUb with respect to R0RBR were similar in all 100 water-refined
complexes, having a backbone rmsd = 0.37  0.02 for the best 20
complexes.
Paramagnetic relaxation enhancement experiments (PRE) were
used to confirm the orientation of the pUb molecule with respect to
the R0RBR protein. Briefly, 12C/14N/2H-labelled cysteine-substituted
Ub (L8C or K48C) was expressed in minimal media, purified and
phosphorylated using Pediculus humanus GST-PINK1 as described
above. Proteins were spin-labelled with 3-(2-iodoacetamido)-PROXYL
(Sigma Aldrich) by incubating each protein with 10 molar equivalents
for 2 h at room temperature and dialysed exhaustively at 4°C. ESI-MS
confirmed quantitative (> 95%) phosphorylation and successful
introduction of spin label (~90 and ~60% spin label incorporation for
L8C and K48C, respectively). 1H-15N TROSY spectra were collected
monitoring 400 lM 13C/15N/2H-R0RBR before and after the addition
of 1.2 molar equivalents of each nitroxide-labelled pUb variant.
Identical spectra were collected following the addition of 10 molar
equivalents of ascorbic acid to quench the nitroxide spin tag. PRE
factors in R0RBR were determined in NMRViewJ by measuring peak
intensities with an active and quenched nitroxide spin tag.
Data and reagents availability
The PDB files of the structures determined in this study have been
deposited with the RCSB Protein Data Bank (www.rcsb.org) with
accession codes 5C1Z (UblR0RBR) and 5C23 (S65DUblR0RBR).
NMR assignments have been deposited to the BMRB (www.bmrb.
wisc.edu) under accession codes 25708 (S65EUb), 25707 (Ub bound
to R0RBR parkin), 25709 (S65EUb bound to R0RBR parkin) and
26605 (Ubl domain bound to R0RBR parkin). Recombinant proteins
and plasmids generated for the present study are available to
request on the MRC-PPU reagents website (https://mrcppureagents.
dundee.ac.uk/).
Expanded View for this article is available online:
http://emboj.embopress.org
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